SYS-CON MEDIA Authors: Liz McMillan, Carmen Gonzalez, Zakia Bouachraoui, Roger Strukhoff, David Linthicum

News Feed Item

Hyperparathyroidism - Analysis and Market Forecasts to 2019

NEW YORK, Nov. 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hyperparathyroidism – Analysis and Market Forecasts to 2019

http://www.reportlinker.com/p01034481/Hyperparathyroidism-–-Analysis-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Hyperparathyroidism – Analysis and Market Forecasts to 2019

Summary

$2.6 billionJuly 2012Scope

- Annualized hyperparathyroidism therapeutics market revenue, annual cost of therapy and forecast for eight years to 2019.

- Pipeline analysis: Comprehensive data split across different phases, emerging trends and mechanisms of action under development, including calcium sensing receptor agonist, vitamin D pro-hormone, vitamin D receptor agonist and CYP24 enzyme inhibitor.

- Analysis of the current and future market competition in the global hyperparathyroidism therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the hyperparathyroidism therapeutics market.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global hyperparathyroidism therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hyperparathyroidism therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global hyperparathyroidism therapeutics market from 2011–2019.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Introduction 92.1 Catalyst 92.2 Related Reports 92.3 Upcoming Related Reports 93 Disease Overview 103.1 Etiology and Pathophysiology 113.1.1 Etiology 113.1.2 Pathophysiology 123.1.3 Risk Factors 133.1.4 Prognosis 143.2 Epidemiology 143.2.1 Prevalence 143.2.2 Diagnosed Prevalence 153.3 Symptoms 163.4 Diagnosis and Referral 163.4.1 Diagnosis 163.4.2 Referral 173.5 Treatment Guidelines 183.6 Disease Management 193.6.1 Primary Hyperparathyroidism 193.6.2 Secondary Hyperparathyroidism 203.6.3 Tertiary Hyperparathyroidism 214 Competitive Assessment 224.1 Overview 224.2 Strategic Competitor Assessment 224.3 Product Profile - Major Brands 244.3.1 Sensipar (cinacalcet) 244.3.2 Zemplar (paricalcitol) 264.3.3 Hectorol (doxercalciferol) 284.3.4 Oxarol (maxacalcitol) 295 Opportunity and Unmet Need 315.1 Overview 315.2 Lower Adverse Effect on Serum Calcium and Phosphorus Level 325.3 New Treatment Options for Primary Hyperparathyroidism 325.4 Disease Awareness and Screening Programs in Primary Hyperparathyroidism 325.5 Convenient Dosing Regimen 325.6 Guidelines for Tertiary Hyperparathyroidism Management 325.7 Pricing 336 Pipeline Assessment 346.1 Overview 346.2 Strategic Pipeline Assessment 346.3 Pipeline by Phases of Development 346.3.1 Phase III Pipeline 346.3.2 Phase II Pipeline 356.3.3 Phase I Pipeline 356.3.4 Preclinical Pipeline 356.3.5 Discovery Pipeline 356.4 Pipeline by Mechanism of Action 366.5 Technology Trends Analytic Framework 376.6 Hyperparathyroidism - Promising Drugs in Clinical Development 386.6.1 CTAP101 396.6.2 KAI-4169 IV 417 Clinical Trials Mapping 437.1 Clinical Trials by Country 437.2 Clinical Trials by Phase 437.3 Clinical Trials by Trial Status 447.4 Prominent Sponsors 448 Current and Future Players 468.1 Overview 468.2 Trends in Corporate Strategy 468.3 Company Profiles 478.3.1 Amgen Inc. 478.3.2 Abbott Laboratories 488.3.3 Cytochroma Inc. 498.3.4 KAI Pharmaceuticals Inc. 508.3.5 Other Companies in the Hyperparathyroidism Therapeutics Market 519 Licensing and Partnership Deals 529.1 Overview 529.2 Key Deals and Alliances in the Past 12 Months 5210 Market Outlook 5310.1 Seven Major Markets Overview 5310.2 Regional Analysis 5510.2.1 US 5510.2.2 France 5610.2.3 Germany 5710.2.4 Italy 5710.2.5 Spain 5810.2.6 UK 5810.2.7 Japan 5910.3 Key Events 5910.4 Drivers and Barriers 6010.4.1 Drivers for the Hyperparathyroidism Market 6010.4.2 Barriers for the Hyperparathyroidism Market 6111 Appendix 6211.1 Abbreviations 6211.2 Bibliography 6311.3 Methodology 6511.3.1 Coverage 6511.3.2 Secondary Research 6511.3.3 Forecasting Methodology 6611.3.4 Primary Research 6811.3.5 Expert Panel Validation 6911.4 Physicians and Specialists Included in this Study 6911.5 About the Authors 6911.5.1 Analysts 6911.5.2 Global Head of Healthcare Research and Consulting 7011.6 About GlobalData 7011.7 Contact Us 7011.8 Disclaimer 70

List of Tables

Table 1: Types of Hyperparathyroidism 11Table 2: Etiology of Primary Hyperparathyroidism 11Table 3: Etiology of Secondary Hyperparathyroidism 12Table 4: Risk Factors for Hyperparathyroidism 13Table 5: Prevalence of Secondary Hyperparathyroidism in Chronic Kidney Disease 14Table 6: Total Prevalence of Hyperparathyroidism in the Major Markets, 2011-2019 15Table 7: Diagnosed Prevalence of Hyperparathyroidism in the Major Markets, 2011-2019 15Table 8: Symptoms of Hyperparathyroidism 16Table 9: Diagnosis of Hyperparathyroidism 17Table 10: Adoption of Treatment Guidelines by Physicians 18Table 11: Treatment Guidelines for Hyperparathyroidism 18Table 12: Surgery Criterion in Primary Hyperparathyroidism 19Table 13: Monitoring Primary Hyperparathyroidism in Nonsurgical Patients 20Table 14: Leading Treatments for Hyperparathyroidism, 2012 22Table 15: Product Profile - Sensipar 24Table 16: Adverse Incidents - Sensipar 25Table 17: Sensipar SWOT Analysis, 2012 26Table 18: Product Profile - Zemplar 26Table 19: Zemplar SWOT Analysis, 2012 27Table 20: Product Profile - Hectorol 28Table 21: Hectorol SWOT Analysis, 2012 29Table 22: Product Profile - Oxarol 29Table 23: Oxarol SWOT Analysis, 2012 30Table 24: Overall Unmet Needs - Current Level of Attainment 31Table 25: Hyperparathyroidism - Phase III Pipeline, 2012 34Table 26: Hyperparathyroidism - Phase II Pipeline, 2012 35Table 27: Hyperparathyroidism - Phase I Pipeline, 2012 35Table 28: Hyperparathyroidism - Preclinical Pipeline, 2012 35Table 29: Hyperparathyroidism - Discovery Pipeline, 2012 35Table 30: Comparison of Mechanisms of Actions in Development for Hyperparathyroidism, 2012 36Table 31: Hyperparathyroidism - Promising Drugs in Clinical Development 38Table 32: Product Profile - CTAP101 39Table 33: CTAP101 SWOT Analysis, 2012 40Table 34: Product Profile - KAI-4169 IV 41Table 35: KAI-4169 IV SWOT Analysis, 2012 42Table 36: Hyperparathyroidism Therapeutics, Clinical Trials by Phase, 2012 43Table 37: Hyperparathyroidism Therapeutics, Clinical Trials by Status, 2012 44Table 38: Hyperparathyroidism - Overall Sponsor Mix, 2012 44Table 39: Key Companies in the Hyperparathyroidism Market, 2012 46Table 40: Amgen's Hyperparathyroidism Therapy Portfolio Assessment, 2012 47Table 41: Amgen's Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 47Table 42: Abbott's Hyperparathyroidism Therapy Portfolio Assessment, 2012 48Table 43: Abbott's Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 48Table 44: Cytochroma's Hyperparathyroidism Therapy Portfolio Assessment, 2012 49Table 45: Cytochroma's Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 49Table 46: KAI Pharmaceutical's Hyperparathyroidism Therapy Portfolio Assessment, 2012 50Table 47: KAI Pharmaceutical's Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 50Table 48: Portfolio Assessment - Other Leading Players in Hyperparathyroidism Market, 2012 51Table 49: Strategic Deals and Alliances for Hyperparathyroidism, 2012 52Table 50: Sales Forecasts for Hyperparathyroidism in the Seven Major Markets, 2011-2019 54Table 51: Sales Forecasts for Hyperparathyroidism in the US, 2011-2019 56Table 52: Sales Forecasts for Hyperparathyroidism in France, 2011-2019 56Table 53: Sales Forecasts for Hyperparathyroidism in Germany, 2011-2019 57Table 54: Sales Forecasts for Hyperparathyroidism in Italy, 2011-2019 57Table 55: Sales Forecasts for Hyperparathyroidism in Spain, 2011-2019 58Table 56: Sales Forecasts for Hyperparathyroidism in the UK, 2011-2019 58Table 57: Sales Forecasts for Hyperparathyroidism in Japan, 2011-2019 59Table 58: Key Events Impacting Sales for Hyperparathyroidism, 2012 59Table 59: Hyperparathyroidism Market - Drivers and Barriers, 2012 60Table 60: Key Launch Dates 66Table 61: Key Patent Expiries 67

List of Figures

Figure 1: Parathyroid Glands 10Figure 2: Pathophysiology of Secondary Hyperparathyroidism 13Figure 3: Referral and Management of Secondary Hyperparathyroidism in CKD Patients 17Figure 4: Strategic Competitor Assessment of Marketed Products in Hyperparathyroidism, 2012 23Figure 5: Opportunity and Clinical Unmet Need in Hyperparathyroidism, 2012 31Figure 6: Hyperparathyroidism Therapeutics Pipeline by Phase of Clinical Development, 2012 34Figure 7: Hyperparathyroidism - Pipeline by Mechanism of Action, 2012 36Figure 8: Technology Trends Analytic Framework for Hyperparathyroidism Pipeline, 2012 37Figure 9: Technology Trends Analytic Framework - Unmet Need Gap Analysis, 2012 38Figure 10: Hyperparathyroidism Therapeutics, Clinical Trials by Country, 2012 43Figure 11: Hyperparathyroidism - Leading Companies Participating in Clinical Trials, 2012 45Figure 12: Sales Forecasts for Hyperparathyroidism in the Seven Major Markets, 2011-2019 54Figure 13: Seven Major Market Sales for Hyperparathyroidism by Region, 2011-2019 55

Companies Mentioned

Amgen Inc.

Abbott Laboratories

Cytochroma Inc.

KAI Pharmaceuticals Inc.

To order this report:Pathology Industry: Hyperparathyroidism – Analysis and Market Forecasts to 2019

Contact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The platform combines the strengths of Singtel's extensive, intelligent network capabilities with Microsoft's cloud expertise to create a unique solution that sets new standards for IoT applications," said Mr Diomedes Kastanis, Head of IoT at Singtel. "Our solution provides speed, transparency and flexibility, paving the way for a more pervasive use of IoT to accelerate enterprises' digitalisation efforts. AI-powered intelligent connectivity over Microsoft Azure will be the fastest connected pat...
There are many examples of disruption in consumer space – Uber disrupting the cab industry, Airbnb disrupting the hospitality industry and so on; but have you wondered who is disrupting support and operations? AISERA helps make businesses and customers successful by offering consumer-like user experience for support and operations. We have built the world’s first AI-driven IT / HR / Cloud / Customer Support and Operations solution.
ScaleMP is presenting at CloudEXPO 2019, held June 24-26 in Santa Clara, and we’d love to see you there. At the conference, we’ll demonstrate how ScaleMP is solving one of the most vexing challenges for cloud — memory cost and limit of scale — and how our innovative vSMP MemoryONE solution provides affordable larger server memory for the private and public cloud. Please visit us at Booth No. 519 to connect with our experts and learn more about vSMP MemoryONE and how it is already serving some of...
Darktrace is the world's leading AI company for cyber security. Created by mathematicians from the University of Cambridge, Darktrace's Enterprise Immune System is the first non-consumer application of machine learning to work at scale, across all network types, from physical, virtualized, and cloud, through to IoT and industrial control systems. Installed as a self-configuring cyber defense platform, Darktrace continuously learns what is ‘normal' for all devices and users, updating its understa...
Codete accelerates their clients growth through technological expertise and experience. Codite team works with organizations to meet the challenges that digitalization presents. Their clients include digital start-ups as well as established enterprises in the IT industry. To stay competitive in a highly innovative IT industry, strong R&D departments and bold spin-off initiatives is a must. Codete Data Science and Software Architects teams help corporate clients to stay up to date with the mod...
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...
Platform9, the leader in SaaS-managed hybrid cloud, has announced it will present five sessions at four upcoming industry conferences in June: BCS in London, DevOpsCon in Berlin, HPE Discover and Cloud Computing Expo 2019.
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
When you're operating multiple services in production, building out forensics tools such as monitoring and observability becomes essential. Unfortunately, it is a real challenge balancing priorities between building new features and tools to help pinpoint root causes. Linkerd provides many of the tools you need to tame the chaos of operating microservices in a cloud native world. Because Linkerd is a transparent proxy that runs alongside your application, there are no code changes required. I...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
"NetApp's vision is how we help organizations manage data - delivering the right data in the right place, in the right time, to the people who need it, and doing it agnostic to what the platform is," explained Josh Atwell, Developer Advocate for NetApp, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Druva is the global leader in Cloud Data Protection and Management, delivering the industry's first data management-as-a-service solution that aggregates data from endpoints, servers and cloud applications and leverages the public cloud to offer a single pane of glass to enable data protection, governance and intelligence-dramatically increasing the availability and visibility of business critical information, while reducing the risk, cost and complexity of managing and protecting it. Druva's...
Kubernetes as a Container Platform is becoming a de facto for every enterprise. In my interactions with enterprises adopting container platform, I come across common questions: - How does application security work on this platform? What all do I need to secure? - How do I implement security in pipelines? - What about vulnerabilities discovered at a later point in time? - What are newer technologies like Istio Service Mesh bring to table?In this session, I will be addressing these commonly asked ...
BMC has unmatched experience in IT management, supporting 92 of the Forbes Global 100, and earning recognition as an ITSM Gartner Magic Quadrant Leader for five years running. Our solutions offer speed, agility, and efficiency to tackle business challenges in the areas of service management, automation, operations, and the mainframe.